that's gotta be out dated given fluoxitine is the front line AD.
The NICE report does not tally with the research they are basing it upon. Which was my point that you can not say they are equally effective.
For example to actually quote one of the meta analysis from the NICE guidelines:
In the present review we assessed the evidence for the efficacy, acceptability and tolerability of citalopram in comparison with all other antidepressants in the acute-phase treatment of major depression. Thirty-seven randomised controlled trials (more than 6000 participants) were included in the present review. In terms of efficacy, citalopram
was more efficacious than other reference compounds like paroxetine or reboxetine, but worse than escitalopram. In terms of side effects, citalopram was more acceptable than older antidepressants, like tricyclics. Based on these findings, we conclude that clinicians should focus on practical or clinically relevant considerations including differences in efficacy and side-effect profiles.
And
Findings
Mirtazapine, escitalopram, venlafaxine, and sertraline
were significantly more efficacious than duloxetine (odds ratios [OR] 1·39, 1·33, 1·30 and 1·27, respectively), fluoxetine (1·37, 1·32, 1·28, and 1·25, respectively), fluvoxamine (1·41, 1·35, 1·30, and 1·27, respectively), paroxetine (1·35, 1·30, 1·27, and 1·22, respectively), and reboxetine (2·03, 1·95, 1·89, and 1·85, respectively). Reboxetine
was significantly less efficacious than all the other antidepressants tested. Escitalopram and sertraline showed the best profile of acceptability, leading to significantly fewer discontinuations than did duloxetine, fluvoxamine, paroxetine, reboxetine, and venlafaxine.
NICE is all about cost effectiveness not best practice. And it is quite clear from the evidence they present that all antidepressants are not equally effective. Hell they are saying the efficacy is not even the same let alone the other aspects eg side-effects which all go to encompass the picture that is effectiveness. Which is why I challenged that assertion. It is misleading and could lead people to make bad decisions.